Mental Help Net
Cancer
Resources
Basic InformationMore InformationLatest News
Cervical Cancer Screening Guidelines UpdatedWatchful Waiting Safe for Some Prostate Cancer PatientsImaging Can Predict Early Response to Cancer TreatmentNew Guidelines Developed for Lung Cancer TherapyMorphine May Help Tumors Spread in Cancer PatientsStudy Links Folic Acid and Vitamin B12 to CancerNervous System Cancer Linked to Cognitive ImpairmentGene Linked to Breast Cancer Might Boost Heart HealthExercise Linked to Less Risk of High-Grade Prostate CancerLab Study Slows Breast Cancer Spread to Bone in MiceDrug May Improve Survival in Head and Neck CancerLeukemia Drug May Help Some Ovarian Cancer PatientsIncreased Cancer Recurrence Linked to High Breast DensityCancer Can Strain Marriages to Breaking PointChronic Pain Can Be a Problem Years After Breast SurgeryAnemia Drugs May Cause Deadly Blood ClotsBreast Cancer Drugs May Fight Cervical Cancer, TooProgram Found to Improve Cancer-Related InsomniaGreen Tea May Help Prevent Oral CancerLow Cholesterol May Decrease Cancer RiskMammography Detection of Breast Cancer Affects MortalityNew HPV Vaccine Might Stop Vulvar Cancer in its TracksMarkers Can Predict Risk of Melanoma RecurrenceShorter, More Intense Radiation OK for Some Breast CancersDrug Could Help Treat Small HER2-Positive Breast TumorsRadiation After Surgery Lowers Chances of Melanoma RecurrenceHormone Therapy Can Help Some With Prostate CancerDelays in Lung Cancer Care More Common in Public HospitalsFive-Minute Survey Can Help Predict Lung CancerProteins Expressed in Liver Cancer May Indicate PrognosisVessel Type Linked to Disease Severity in Prostate CancerHealth Tip: Screening for CancerACG: Racial Disparities Seen in Colorectal CancerTesticular Cancer Survivors Face Other IllsRadiologists May Be Reluctant to Disclose Mammography ErrorsMeditation May Reduce Stress in Breast Cancer PatientsFDA: Arzerra Approved for Chronic Lymphocytic LeukemiaAdding Chemo Helps Head, Neck Cancer PatientsMapping the Link Between Alcohol, CancerProtein Linked to Development of Some Lung CancersLow-Dose Regimen Found to Improve Myeloma SurvivalStudy Finds Less Toxic Treatment for MyelomaAmerican Cancer Society Stands By Cancer Screening GuidelinesRadiation Treatments Made Safer for Cancer PatientsVotrient Approved for Advanced Kidney CancerPSA 'Nanotest' May Spot Prostate Cancer's Return After SurgeryMore Doctors Need to Learn to Spot Skin CancersStudy Assesses Testicular Cancer Survivors' SymptomsDrugs for Inflammatory Bowel Might Increase Cancer RiskOncologists May Often Fail to Refer for Fertility Counseling
Blog EntriesVideosLinksBook Reviews
Community

Talk about this issue in our mental health support community

Therapist Search
Find a Therapist:
 (USA/CAN only)

Use our Advanced Search to locate a therapist outside of North America.

Related Topics

Medical Disorders
Pain Management

Markers Can Predict Risk of Melanoma Recurrence

(HealthDay News)
by -- A. Agrawal, PhD
Updated: Nov 4th 2009

new article illustration

WEDNESDAY, Nov. 4 (HealthDay News) -- Levels of five markers can identify patients at high risk of recurrent melanoma who could benefit from additional treatment, according to a study published online Nov. 2 in the Journal of Clinical Oncology.

Bonnie E. Gould Rothberg, M.D., and colleagues from the Yale University School of Medicine in New Haven, Conn., evaluated the expression of 38 protein markers relevant to melanoma oncogenesis in 192 primary melanomas using an automated quantitative analysis method for immunofluorescence-based immunohistochemistry.

By developing a genetic algorithm, the researchers found that five markers could identify patients at high risk of recurrence. Patients below particular cutoff values for at least four of the markers were considered at low risk, while patients below these values for three or fewer markers were considered at high risk. After adjusting for various clinical and pathological factors, patients in the high-risk group had significantly lower survival (hazard ratio, 2.84), as did patients in a predicted high-risk group from an independent group of 246 primary melanomas (hazard ratio, 2.72).

"This multimarker prognostic assay, an independent determinant of melanoma survival, might be beneficial in improving the selection of stage II patients for adjuvant therapy," Rothberg and colleagues conclude.

Several authors reported financial relationships with HistoRx.

Abstract
Full Text (subscription or payment may be required)

Follow us on Twitter!

Find us on Facebook!





powered by centersite dot net